Related Experiment Video
Updated: Jan 28, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
An Autopsy Case of Pleural Mesothelioma Progressed Rapidly With Multiple Organ Metastases During Immune Checkpoint
Mihoko Yamamoto-Rikitake1, Takeshi Yamaryo2, Kazuki Nabeshima3
1Department of Pathology, Nagasaki Rosai Hospital, Nagasaki, Japan.
Abstract:
Immune checkpoint inhibitors (ICIs) were approved in Japan in 2021 for the initial treatment of pleural mesothelioma (PM), offering anticipated prognostic benefits. However, reports of atypical responses exist. We report the case of an 80-year-old man with PM who, despite primary tumor shrinkage on ICI treatment, died of small intestinal perforation resulting from rapid, multiorgan metastasis. This case provided an opportunity to examine the histological changes in PM post-ICI treatment. The rapid clinical course was suggestive of hyperprogressive disease (HPD), a pattern of unexpectedly accelerated progression. Atypical response patterns remain rare in PM, and it is noteworthy that in this case fulminant metastatic progression occurred concurrently with marked regression of the primary pleural lesion. We believe this is a significant case worthy of presentation.
Insights
Immune checkpoint inhibitors (ICIs) can cause atypical responses in pleural mesothelioma (PM). This case highlights rapid metastasis despite primary tumor shrinkage, suggesting hyperprogressive disease (HPD) is possible.
Area of Science:
- Oncology
- Immunotherapy
- Malignant Pleural Mesothelioma
Background:
- Immune checkpoint inhibitors (ICIs) were approved for initial pleural mesothelioma (PM) treatment in Japan in 2021.
- While offering prognostic benefits, atypical responses to ICIs have been reported.
Related Concept Videos
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
Pleural Effusion I: Introduction
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Pleural Disorders: Types and Brief Description
Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
What is the Immune System?

